Jul 2, 2026 11:45AM

Jul 2, 2026 11:45AM

Apr 29, 2026 11:50AM

Mar 24, 2026 07:00AM

Dec 8, 2025 07:00AM

Sep 16, 2025 07:00AM

Aug 12, 2025 07:00AM Newron Begins Enrollment in Pivotal Phase III ENIGMA-TRS Program With Evenamide as Add-on Therapy in Patients With Treatment-Resistant Schizophrenia (TRS)

May 12, 2025 07:00AM

Sep 19, 2024 07:00AM

Mar 19, 2024 07:00AM

Aug 4, 2023 07:00AM

Mar 14, 2023 07:00AM

Sep 15, 2022 07:00AM

Mar 15, 2022 07:00AM Newron Announces 2021 Financial Results and Provides Outlook for 2022

Sep 16, 2021 07:00AM

May 20, 2021 07:00AM

May 4, 2021 07:00AM

Apr 1, 2021 07:00AM

Mar 16, 2021 07:00AM

Mar 15, 2021 07:00AM

Jan 21, 2021 07:00AM Newron Completes Enrollment of Explanatory Safety and Efficacy Study With Evenamide in Schizophrenia Patients

Sep 15, 2020 07:00AM

Mar 11, 2020 07:00AM

Mar 5, 2020 07:00AM

Nov 19, 2019 07:00AM

329,068 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All